Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
With Trump’s new FDA commish nominee looming, industry execs are keeping their fingers crossed for Scott Gottlieb
9 years ago
Biotech dealmaker Ramaswamy raises another $55M for Axovant
9 years ago
Financing
Cytokinetics chief Blum grabs $100M royalty deal to fund an expanded marketing plan for PhIII heart drug
9 years ago
Big Pharma promised Trump new American jobs for tax cuts and deregulation. But the vow comes after a 5-year purge
9 years ago
Analysts write off Dimension’s lead program after seeing weak data on hemophilia B, shares plunge
9 years ago
Trump scolds pharma execs, demanding lower prices, more US manufacturing while promising to slash FDA regs
9 years ago
On a deal spree, Takeda grabs Japanese cabo rights in $145M pact with Exelixis
9 years ago
FibroGen, AstraZeneca ready China application as anemia drug scores in two pivotal studies
9 years ago
R&D
China
Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front
9 years ago
Biotech execs slam Trump’s travel ban, counting the high cost to a global industry
9 years ago
Endpoints Video spotlight: The debate over drug pricing takes center stage in 2017
9 years ago
Experts fret over a new hiring freeze at the FDA. Will the fallout be toxic to drug reviews?
9 years ago
Ex-Mela chief Gulfo joins the list of would-be FDA commish candidates, color-coded drug approval plan in hand
9 years ago
Women are gaining more board seats in biotech, but real change is happening at a snail's pace
9 years ago
R&D
Banned from Twitter, Martin Shkreli whips up a new online tirade in response to a mocking dig from PhRMA chief
9 years ago
Facing a deepening political crisis, PhRMA launches a major counterattack against its legion of critics
9 years ago
After repeated setbacks on the checkpoint front, Bristol-Myers scores a $625M payout from Merck to settle patent fracas
9 years ago
The FDA’s cautionary Hall of Shame: 22 ‘breakthrough’ drugs that suddenly crashed in PhIII
9 years ago
Bristol-Myers staggered by a stunning checkpoint setback, hands Merck a free pass on frontline lung cancer combo
9 years ago
R&D
Synergy bags an FDA OK for constipation therapy Trulance in the lead up to an sNDA
9 years ago
Ovid and Takeda create a one-team strategy to steer a neuro drug to the world
9 years ago
SEC hands Allergan a $15M speeding ticket for blowing off disclosure rules in a tough 2014 fight against Valeant
9 years ago
Biogen to pay $1.25B to de-risk a Tecfidera patent battle, and Forward Pharma’s shares rocket up
9 years ago
In his latest broadside on drug prices, Trump plays the Medicare negotiations card
9 years ago
First page
Previous page
334
335
336
337
338
339
340
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit